The US FDA issues consent decree of permanent injunction against Ben Venue Laboratories.
M2 PHARMA-February 5, 2013-The US FDA issues consent decree of permanent injunction against Ben Venue Laboratories(C)2013 M2 COMMUNICATIONS
The US Food and Drug Administration (FDA) has stated that the federal judge has issued a consent decree of permanent injunction against Ben Venue Laboratories, a subsidiary of Boehringer Ingelheim, and three of its corporate officers, it was reported yesterday.
The consent decree of permanent injunction has been issued for failing to meet with present good manufacturing practice requirements as required by federal law.
The decree was signed by the US District Court for the Northern District judge Lesley Wells of Ohio on 31 January 2013, and was issued to the company's chief executive officer, vice president of operations and vice president of quality operations.
((Comments on this story may be sent to email@example.com)).END.PUB430>PDFebruary 5, 2013>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 5, 2013|
|Previous Article:||Cerulean Pharma doses first patient in Phase 2 study of CRLX101 drug.|
|Next Article:||MDH Radiology signs contract with Sectra.|